secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2024-07-09T23:59:59+00:00
Accession:  0001104659-24-078451
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma reports 75% ctDNA reduction in HER2 3+ patients in Phase 1 CT-0508 trial
--------------------------------------------------------------------------------

- 75% (6/8) evaluable HER2 3+ patients had ctDNA reduction (median 81%, range 33%-93%); no reduction in 5 HER2 2+ patients.
- Best overall response: stable disease in 44% (4/9) of HER2 3+ patients; all HER2 2+ patients had progressive disease.
- Phase 1 CT-0508 enrollment halted April 2024; all patient activities completed as of July 2024.
- Company expects clinical data updates in Q3 2024 and initial Phase 1 data for follow-on CT-0525 in Q4 2024.
- Preliminary data supports mechanism of action and potential for repeat dosing with CT-0525 in HER2 overexpressing cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924078451/0001104659-24-078451-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924078451/tm2419051d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-078451

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer